Lycera Raises $11M Second Tranche in Series A Financing

Lycera Corporation, a biopharmaceutical company focused on the discovery and development of selective, small-molecule immunomodulators for the treatment of patients with autoimmune diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, has raised a second tranche of $11m in its Series A financing.
The new capital will be used to continue to advance Lycera’s discovery and development efforts and further support the growth of the company.
In conjuction with the funding, Jeffrey Leiden, M.D., Ph.D., managing director at Clarus Venture Partners, joins the company as chairman of the board of directors. In addition, as a result of the company’s progress towards the clinic, Dr. Goldstein joins as the vice president, preclinical development and program management.
Founded in 2006, the company is headquartered in Cambridge, Mass. and has a research center in Ann Arbor, Mich.



Join the discussion